Drug intelligence / Profile preview

PtCl(phpy)(PTA)

Development stage: Preclinical
Modality: Small Molecules

Overview

PtCl(phpy)(PTA) is a cyclometallated platinum(II) complex featuring a 2-phenylpyridine (phpy) ligand and a 1,3,5-triaza-7-phosphaadamantane (PTA) phosphine ligand. This organometallic compound is part of a series of complexes designed to modulate biological activity through phosphine ligand substitution. Preclinical studies indicate that the PTA derivative possesses selective antileishmanial activity, significantly reducing infectivity in parasitic models, and selective antitumor activity against ovarian cancer cell lines. Its mechanism of action involves ligand exchange with sulfur- and nitrogen-containing biomolecules, as well as direct interaction with DNA and serum proteins like bovine serum albumin (BSA).

Other names: chloro(2-phenylpyridine)(1,3,5-triaza-7-phosphaadamantane)platinum(II)[Pt(II)(phpy)(PTA)Cl]

Targets

DNA

Beyond the preview

Go deeper on PtCl(phpy)(PTA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PtCl(phpy)(PTA).

Explore the full profile